Non-insulin oral drug(s)-Glucophage (Metformin) Posts on Medivizor
Navigation Menu

Non-insulin oral drug(s)-Glucophage (Metformin) Posts on Medivizor

FDA Recalls

FDA Recalls

Posted by on May 31, 2020 in Blog, Diabetes mellitus | 0 comments

You may not realize it but your diabetes medication, metformin extended release, has been recalled. One of the places to look for information on recalls of medications is the Recalls, Market Withdrawals, & Safety Alerts page on the FDA website. The recall, on May 28, is for Metformin Hydrochloride Extended-Release Tablets, USP 500mg by a...

Read More

The effect of semaglutide versus sitagliptin as add-on therapy for type 2 diabetes

Posted by on Apr 13, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to compare the effects of adding semaglutide versus sitagliptin onto metformin with or without a sulfonylurea in type 2 diabetes (T2D). The main finding was that adding 7mg or 14mg semaglutide on to metformin/sulphonylurea therapy showed greater improvements in blood sugar control compared to sitagliptin. Some...

Read More

Looking for patients with type 2 diabetes to test a new treatment tirzepatide

Posted by on Feb 27, 2019 in Diabetes mellitus | 0 comments

In a nutshell This trial is examining the effectiveness of tirzepatide compared to insulin glargine in patients with type 2 diabetes who are also at high risk for heart disease. The main outcome to be measured will be a change in HbA1c (a blood test that measures average blood sugar levels in the past 3 months) over 52 weeks. The details In type 2...

Read More

Searching for patients with type 2 diabetes to test the effectiveness of the drug semaglutide compared to other standard treatments

Posted by on Dec 15, 2018 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study is to test the effectiveness of semaglutide (Ozempic) in the treatment of type 2 diabetes compared to other currently used treatments. The main outcome to be measured is the change in HbA1c (blood test measuring blood sugar control over 3 months). This study is being conducted in the United States. The details...

Read More

Looking for young people with type 2 diabetes to try dapagliflozin and saxagliptin

Posted by on Aug 31, 2018 in Diabetes mellitus | 0 comments

In a nutshell This phase 3 clinical trial is investigating the safety and effectiveness of dapagliflozin (Forxiga) and saxagliptin (Onglyza) in young people with type 2 diabetes (T2D). The main outcome to be measured will be change in HbA1c (measures average blood glucose over the last 3 months) after 6 months of treatment. The details Dapagliflozin...

Read More

Investigating a combination of ertugliflozin and sitagliptin in people with type 2 diabetes

Posted by on Jan 26, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the effectiveness and safety of ertugliflozin (Steglatro) plus sitagliptin (Januvia), compared to either drug used alone, in people with type 2 diabetes (T2D). It was determined that the combination was better at controlling blood glucose levels, without increasing the risk of side effects. Some background...

Read More